Fragment 176-191
low riskAlso: HGH Fragment 176-191 · HGH Frag · Fat loss peptide
Fragment 176-191 is a C-terminal HGH fragment associated with fat metabolism. Related to AOD-9604. Animal studies show selective lipolytic effects. Human clinical data is very limited — primarily animal and anecdotal. Heavily marketed but evidence is thin.
Reported Benefits
Lipolysis / fat reduction
Animal models show selective fat reduction. Human data essentially anecdotal.
Mechanism of Action
Selectively activates lipolysis without affecting IGF-1 or insulin sensitivity via C-terminal HGH mechanism.
AOD-9604 vs. Fragment 176-191
Closely related compounds — AOD-9604 is the modified/stabilized version. AOD-9604 at least has Phase III trial data (even though it failed). Fragment 176-191 human data is essentially absent beyond Phase I safety.
Evidence claims circulating online significantly exceed what the actual research supports.
Regulatory Status
Research OnlySafety Profile
Side Effects
- •Mild injection site reactions
- •Possible mild hypoglycemia
Contraindications
- •Pregnancy
Primary Uses
Related Peptides
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe Fragment 176-191?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →